A judge on Thursday allowed the bosses of French bank BNP Paribas to appeal an earlier decree ordering them to come to Malta to testify in a €1 billion anti-semitism lawsuit filed by a Maltese investment house and its founder, Malta-based businessman Jacob Agam.
Mr Justice Joseph Zammit McKeon had already ordered the chairman and the CEO of the bank to appear in court to testify but they resisted the order, arguing that they could not be forced to come to Malta to testify.
They filed an application in court to appeal the summons and the judge ruled that it would be “better and fairer” if the matter is decided by a Court of Appeal prior to final judgment given the exceptional circumstances of the case.
BNP Paribas ‘anti-semitism’ row: Malta judge says bank can appeal summons
Top brass from BNP Paribas will be allowed to appeal a court decree to testify in Malta in a case filed against them by British financer Jacob Agam
25 February 2021, 4:00pm
by Matthew Agius
A judge hearing a million-euro case filed against French bank BNP Paribas by a Malta-based investment house, has granted the bank special permission to appeal a decree in which he had ordered its CEO to testify.
The decree was handed down by Mr Justice Joseph Zammit Mckeon in the lawsuit filed by Vertical Group Holding, a Maltese investment house and its founder and chairman, the Malta-based, British businessman Jacob Agam, against BNP Paribas, its chairman Jean Lemierre and CEO Jean-Laurent Bonnafé.
A judge is expected to rule next week whether the bosses of French bank BNP Paribas can refuse to appear in court in Malta to testify in a €1 billion anti-semitism lawsuit filed by a Maltese investment house and its founder, Malta-based businessman Jacob Agam.
Mr Justice Joseph Zammit McKeon had already ordered the chairman and the CEO of the bank to appear in court to testify, but they resisted the order, arguing that they could not be forced to come to Malta to testify.
Malta-based businessman Jacob Agram
In a sitting scheduled for Thursday next week, the judge is expected to rule whether to enforce his order, issued last August, with the possibility of escalating it to a warrant of arrest if the pair failed to appear.
Carlsmed Raises $10M to Commercialize Breakthrough aprevo™ Devices Today, Carlsmed, Inc. announces the close of a $10M Series A financing to commercialize the
aprevo family of spine deformity correction devices. The San Diego-based medical device company is focused on improving outcomes for patients with adult spinal deformity. Carlsmed has pioneered a novel digital + surgical solution to create optimized surgical plans and personalized
aprevo implants to enable superior correction of the spinal deformity. This round of financing is led by U.S. Venture Partners (USVP) and includes participation from The Vertical Group, Cove Fund, and Wavemaker Three-Sixty Health, among others. This round of financing comes at the perfect time to meet surgeon and patient demand for the newly launched Breakthrough
Carlsmed, Inc., a San Diego, CA-based medical device company, closed a $10M Series A financing round.
The round was led by U.S. Venture Partners with participation from The Vertical Group, Cove Fund, and Wavemaker Three-Sixty Health, among others.
The company intends to use the funds to commercialize its devices.
Led by Mike Cordonnier, CEO, Carlsmed is the maker of the
aprevo family of spine deformity correction devices. Its novel digital + surgical solution creates optimized surgical plans and personalized implants to enable superior correction of the spinal deformity.
In conjunction with the Series A closing, the company announced the appointment of three directors to the board, Jonathan Root, M.D., Phil Young, and Kevin Sidow.